Trial Success Sets Up Roche’s Alecensa To Be First ALK+ Drug In Adjuvant NSCLC
Will Help Sustain Class Leadership
Roche has suffered many setbacks in its NSCLC pipeline, so clear signs of Phase III success from Alecensa in the adjuvant setting are welcome for the company.
